CANCER IS THE LEADING CAUSE OF DEATH WORLDWIDE
1-4
1,2
3
4
Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth, local tissue invasion and distant metastases
Approximately 18 million new cases and 9 million deaths from cancer occur annually
Up to 1/3 of people will be
diagnosed with cancer
by the age of 75 years
1. American Cancer Society. What is cancer? Available at: https://www.cancer.org/cancer/cancer-basics/what-is-cancer.html. Last accessed May 2021. 2. MedicineNet. Medical definition of cancer. Available at: https://www.medicinenet.com/script/main/art.asp?articlekey=2580. Last accessed May 2021. 3. Ferlay J et al. Int J Cancer 2019;144:1941–53. 4. The Cancer Atlas. Europe. Available at: https://canceratlas.cancer.org/the-burden/europe/. Last accessed May 2021.
MOST COMMON CANCERS INCLUDE
LUNG, BREAST AND COLORECTAL
1
MOST COMMONLY DIAGNOSED CANCERS
• Colorectal cancer 1.80 million
• Prostate cancer 1.28 million
• Non-melanoma skin cancer 1.04 million
1. Ferlay J et al. Int J Cancer 2019;144:1941–53.
MOST COMMON CAUSES OF CANCER DEATH
• Colorectal cancer 861,000 deaths
• Stomach cancer 783,000 deaths
• Liver cancer 782,000 deaths
• Breast cancer 627,000 deaths
BREAST CANCER
1
-
Oyavas®, in combination with paclitaxel, is indicated for first-line treatment of adult patients with metastatic breast cancer
-
Oyavas®, in combination with capecitabine, is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options, including taxanes or anthracyclines, is not considered appropriate*
*Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Oyavas® in combination with capecitabine 1. Oyavas® SmPC (Apr. 2021).
CERVICAL CANCER
1
Oyavas®, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix
1. Oyavas® SmPC (Apr. 2021).
COLORECTAL CANCER
1
Oyavas®, in combination with fluoropyrimidine-based chemotherapy, is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum
1. Oyavas® SmPC (Apr. 2021).
LUNG CANCER
1
-
Oyavas®, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent NSCLC other than predominantly squamous cell histology
-
Oyavas®, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous NSCLC with EGFR-activating mutations
1. Oyavas® SmPC (Apr. 2021).
1
OVARIAN CANCER
-
Oyavas®, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of adult patients with advanced (FIGO stages IIIb, IIIc and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer
-
Oyavas®, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents
-
Oyavas®, in combination with topotecan, or pegylated liposomal doxorubicin, is indicated for the treatment of adult patients with platinum‑resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab, other VEGF inhibitors or VEGF receptor‑targeted agents
FIGO, International Federation of Gynecology and Obstetrics; VEGF, vascular endothelial growth factor 1. Oyavas® SmPC (Apr. 2021).
RENAL CELL CANCER
1
Oyavas®, in combination with interferon alfa-2a, is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer
1. Oyavas® SmPC (Apr. 2021).
